Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation
Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation Represents second approved indication for Restylane Defyne in U.S.; expands Galderma Aesthetics' growing Restylane product portfolio News provided by Share this article Share this article FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ -- Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. 1 In 2020 alone, online searches for chin enhancement increased by 185 percent, rei...
Source: prnewswire.com